GLAS
Global Loan Agency Services Limited (part of the global GLAS Group) is thrilled to announce the successful completion of its acquisition of Pristine. This marks the first acquisition by the GLAS Group, and also represents a key milestone in the organisation’s ambitious roadmap to deepen its presence in Europe.
This transaction was agreed in August 2023 subject to regulatory approval and customary closing conditions, with completion occurring in March 2024.
Pristine
Pristine is a leading fiducie and asset management business. It was established in Paris in 2016 and is regulated by the Autorité des Marchés Financiers (AMF).
Pristine provides a complementary set of services which include fiducie, fund structuring and administration services to both international and domestic institutions with the primary purpose of facilitating corporate financing activity for non-bank and bank lenders in France.
The firm has a deep and diversified history in restructuring, securitisation, structured finance, and other ad hoc financing projects.
GLAS France
The GLAS Group launched its French operations in Paris in 2018 and has since built out a sizeable team led by Aymeric Mahe, Head of GLAS SAS.
GLAS SAS is the only non-bank, independent company regulated by the Autorité de Contrôle Preduentiel et de Résolution (ACPR) to administer payments in France on loan transactions that forms part of a global group.
In addition to loan agency services, GLAS provides a range of institutional debt administration to domestic and international debt funds, corporates, and bulge bracket banks globally.
The firm is a market-leading provider in direct and syndicated lending, high yield, leveraged finance and capital market debt issuance.
GLAS SAS has also been involved with numerous high-profile restructuring cases in France such as SMCP, Orpea, Technicolor and Pierre & Vacances.
GLAS founders Mia Drennan and Brian Carne said:
“We are excited to finalise the Group’s first ever acquisition and further expand GLAS’s service capabilities. The AMF and ACPR regulatory permissions of Pristine and GLAS, along with our collective expertise and reputations in the debt markets, will allow us to offer an expanded offering of relevant services to our enlarged client base.”
Pristine Président, Renaud Baboin said:
“This acquisition signals the start of a fantastic partnership between GLAS and Pristine. The two companies are well matched across all aspects of the respective businesses and culture, and I am excited to see how the respective businesses flourish as a result."
Pristine Directeur Général, Benjamin Raillard added:
“We are happy to announce the closure of this transaction and begin integrating Pristine with the GLAS Group. It is an exciting time for the group and our customers who will soon be able to benefit from the synergies of the two organisation’s expertise. We are confident that this partnership will be a fruitful one for all involved.”
GLAS and Pristine’s plan for the future
The conclusion of this acquisition signifies GLAS’s commitment to offering an expanded suite of products and services to meet the needs of clients who participate in originating debt or investing in financial transactions in Europe.
The Pristine team will be located at GLAS SAS’s new Paris office on Avenue George V.
The two organisations will be continue to be separately regulated by the AMF and the ACPR. The two licences will allow GLAS and Pristine to offer an enhanced service to more customers on a greater number of transactions.
Since the original announcement of the proposal to acquire Pristine, GLAS have also, subject to regulatory approval, committed to partnering with Singaporean-based Watiga. Watiga will also join the GLAS Group’s global network.
About GLAS
GLAS was established in 2011 by Mia Drennan and Brian Carne. Today, it is the premier independent, non-creditor, conflict-free provider of loan administration and bond trustee services known for its white glove service and expertise on complex deal execution.
GLAS is a global company and is located in the USA, Europe, and APAC, with headquarters in London. GLAS services in excess of €360bn of assets under administration on a daily basis and employs over 300 professionals in the Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401726218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
